Organovo - VIVS Total Company Value-to-Revenue Ratio

Organovo Holdings (VIVS) - corporate logo

VivoSim Labs Inc (VIVS) is implementing automated 3D bioprinting systems to create living tissues. The enterprise value-to-revenue ratio demonstrates the asset's valuation dynamics, where the -15357.14 mark records this metric. VivoSim Labs Inc (VIVS) is expanding its B2B presence in the medical equipment sector, while long-term revenue is based on licensing unique organ models to pharmaceutical behemoths.

Organovo Holdings Inc. (VIVS) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Organovo Holdings (VIVS)

- share price and consensus valuation forecast:
Fundamental company valuation:VIVS, VivoSim Labs Inc
Flagship merchandise of Organovo

To identify fundamental benchmarks in the financial statements of VivoSim Labs Inc. (VIVS), it is critical to analyze the enterprise value including net debt relative to sales volume. The company's EV/Sales ratio allows for an assessment of the asset's overvaluation, which is particularly relevant when adapting bioprinting technologies to meet the demands of pharma behemoths and monitoring commercial partnerships to identify undervalued shares.